CF Industries Holdings, Inc. logo CF - CF Industries Holdings, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 21
HOLD 14
SELL 6
STRONG
SELL
0
| PRICE TARGET: $110.00 DETAILS
HIGH: $145.00
LOW: $72.00
MEDIAN: $109.00
CONSENSUS: $110.00
DOWNSIDE: 9.42%

Stock News

CF Industries Holdings, Inc. Announces 20% Increase in Quarterly Dividend

CF Industries Holdings, Inc. Announces 20% Increase in Quarterly Dividend

NORTHBROOK, Ill.--(BUSINESS WIRE)--CF Industries Holdings, Inc. (NYSE: CF) today reported that its board of directors has declared a $0.60 per share dividend on its common stock, a 20% increase compared to its prior quarterly dividend. The dividend will be payable on August 31, 2026, to stockholders of record as of August 14, 2026. Additionally, the Company confirmed that it will report its second quarter and first half 2026 results after the market close on Wednesday, August 5, 2026. The compa.

Jul 08, 2026 12:30 PM businesswire.com
Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseases

Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseases

First-in-human Phase 1 study in 56 healthy participants demonstrated KIT2014's safety and tolerability KIT2014 is being developed as an inhalation therapy for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis (NCFB) and cystic fibrosis (CF) KIT2014's unique mode of action improves respiratory symptoms by promoting bronchodilation and reducing lung inflammation TURIN, Italy, June 19, 2026 (GLOBE NEWSWIRE) -- Kither Biotech Pty Ltd and Kither Biotech srl, a clinical-stage biopharmaceutical group of companies developing innovative therapies for respiratory diseases, today announced the successful completion of their Phase 1 clinical study of KIT2014 in healthy participants. “We are pleased to report the successful completion of this first-in-human Phase 1 study with KIT2014, a significant milestone for Kither Biotech,” said Dr. Dimitrios Goundis, CEO of Kither Biotech.

Jun 18, 2026 11:30 PM globenewswire.com

Price Targets